Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIL 214

Next Previous
Drug Profile

HIL 214

Alternative Names: HIL-214; Norovirus bivalent vaccine - Takeda; Norovirus bivalent VLP vaccine; Norovirus GI.1/GII.4 bivalent VLP vaccine; Norovirus IM vaccine - Takeda; Norovirus intramuscular vaccine - Takeda; TAK-214

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer HilleVax; Takeda
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Norovirus infections
  • Phase II Gastroenteritis

Most Recent Events

  • 10 Jul 2025 HilleVax terminates a phase II/III trial for Norovirus infections (Prevention, In infants) (IM, Injection) in USA, Panama, Dominican Republic, Puerto Rico, Honduras, Colombia and Peru due to lack of efficacy (NCT05281094)
  • 08 Jul 2024 HilleVax completes a phase II trial in Norovirus infections (In infants, Prevention) in USA, Panama, Puerto Rico (IM) (NCT05836012)
  • 08 Jul 2024 Immunogenicity, efficacy and adverse events data from the phase II/III NEST-IN1 trial in Norovirus infections released by HilleVax

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top